Research programme: antiviral vaccines - Integrated BioTherapeutics/Integral Molecular

Drug Profile

Research programme: antiviral vaccines - Integrated BioTherapeutics/Integral Molecular

Latest Information Update: 06 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Integral Molecular; Integrated BioTherapeutics
  • Class Antivirals; Viral envelope proteins; Viral vaccines; Zika virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Ebola virus infections; Zika virus infection

Most Recent Events

  • 02 Mar 2017 Integrated BioTherapeutics and Integral Molecular enter into an agreement for the development of vaccines against Ebola virus infections and Zika virus infection
  • 02 Mar 2017 Preclinical trials in Ebola virus infections in USA (Parenteral)
  • 02 Mar 2017 Preclinical trials in Zika virus infection in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top